Entresto, Novartis AG’s approved heart failure drug, has failed in a Phase III trial in an indication that promised to double the patient population for the product. The PARAGON-HF trial data have been keenly awaited as a key catalyst with the potential to lead to a big increase in sales and profitability of the dual-acting drug.
Entresto (sacubitril/valsartan), which is already approved to treat patients with heart failure with reduced ejection fraction (HFrEF), was being studied...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)